These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31118216)

  • 1. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.
    Hinchcliff E; Westin SN; Dal Molin G; LaFargue CJ; Coleman RL
    Int J Gynecol Cancer; 2019 May; ():. PubMed ID: 31118216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    Hinchcliff E; Chelariu-Raicu A; Westin SN
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):19-25. PubMed ID: 33315700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer.
    Dong R; Ding T; Li Z
    Front Pharmacol; 2023; 14():1164395. PubMed ID: 37426808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
    Le Saux O; Vanacker H; Guermazi F; Carbonnaux M; Roméo C; Larrouquère L; Trédan O; Ray-Coquard I
    Future Oncol; 2021 Jun; 17(18):2291-2304. PubMed ID: 33726504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
    AlGhamdi A; AlMubayedh H
    Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions.
    Caruso G; Tomao F; Parma G; Lapresa M; Multinu F; Palaia I; Aletti G; Colombo N
    Int J Gynecol Cancer; 2023 Apr; 33(4):431-443. PubMed ID: 36928097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    Vanacker H; Romeo C; Ray-Coquard I
    Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
    Hottiger MO
    Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
    Chelariu-Raicu A; Trillsch F; Burges A; Czogalla B; Hester A; Wuerstlein R; Harbeck N; Mahner S
    Int J Gynecol Cancer; 2023 May; 33(5):812-822. PubMed ID: 36707086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    Li J; Li Q; Zhang L; Zhang S; Dai Y
    Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic applications of PARP inhibitors in ovarian cancer.
    Xie H; Wang W; Xia B; Jin W; Lou G
    Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
    Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A
    Front Oncol; 2021; 11():745981. PubMed ID: 34778062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
    Pham MM; Avila M; Hinchcliff E; Westin SN
    Cancer Treat Res; 2023; 186():71-89. PubMed ID: 37978131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    Washington CR; Moore KN
    Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.